T-box 2 (TBX2) is a transcription factor involved in mammary development and is known to be overexpressed in a subset of aggressive breast cancers. TBX2 has previously been shown to repress growth control genes such as p14 ARF and p21 WAF1/cip1 . In this study we show that TBX2 drives proliferation in breast cancer cells and this is abrogated after TBX2 small interfering RNA (siRNA) knockdown or after the expression of a dominant-negative TBX2 protein. Using microarray analysis we identified a large cohort of novel TBX2-repressed target genes including the breast tumour suppressor NDRG1 (N-myc downregulated gene 1). We show that TBX2 targets NDRG1 through a previously undescribed mechanism involving the recruitment of early growth response 1 (EGR1). We show EGR1 is required for the ability of TBX2 to repress NDRG1 and drive cell proliferation. We show that TBX2 interacts with EGR1 and that TBX2 requires EGR1 to target the NDRG1 proximal promoter. Abrogation of either TBX2 or EGR1 expression is accompanied by the upregulation of cell senescence and apoptotic markers. NDRG1 can recapitulate these effects when transfected into TBX2-expressing cells. Together, these data identify a novel mechanism for TBX2-driven oncogenesis and highlight the importance of NDRG1 as a growth control gene in breast tissue.
T-box 2 (TBX2) is a transcription factor involved in mammary development and is known to be overexpressed in a subset of aggressive breast cancers. TBX2 has previously been shown to repress growth control genes such as p14 ARF and p21 WAF1/cip1 . In this study we show that TBX2 drives proliferation in breast cancer cells and this is abrogated after TBX2 small interfering RNA (siRNA) knockdown or after the expression of a dominant-negative TBX2 protein. Using microarray analysis we identified a large cohort of novel TBX2-repressed target genes including the breast tumour suppressor NDRG1 (N-myc downregulated gene 1). We show that TBX2 targets NDRG1 through a previously undescribed mechanism involving the recruitment of early growth response 1 (EGR1). We show EGR1 is required for the ability of TBX2 to repress NDRG1 and drive cell proliferation. We show that TBX2 interacts with EGR1 and that TBX2 requires EGR1 to target the NDRG1 proximal promoter.
Introduction
The 17q23 amplicon is observed in approximately 20% of primary breast tumours, and is more common in high-grade tumours and in BRCA1 and BRCA2 mutation carriers (Tirkkonen et al., 1997; Roylance et al., 1999) . One gene consistently amplified from the 17q23 region is T-box 2 (TBX2; Sinclair et al., 2002) . TBX2 is a member of the T-box family of transcription factors, which have important roles in developmental gene regulation (Chapman et al., 1996) . T-box proteins bind DNA and regulate gene expression through highly conserved 180-200 amino acid T-box motifs. Genetic studies from Xenopus to humans point to a crucial role of T-box proteins in controlling development in a gene dose-dependent manner. TBX2 is normally expressed in the milk ridge during the development of the duct system of the mammary gland in the mouse (Chapman et al., 1996) . Its closest family member TBX3 is also involved in mammary development, specifically mammary bud development.
The TBX2 link to cancer was first shown by its ability to facilitate senescence bypass in Bmi À/À mouse embryo fibroblasts when moderately overexpressed (Jacobs et al., 2000) . TBX2 was found to be a potent immortalizing gene that exerted an effect by downregulating Cdkn2a (p19 ARF , p14 ARF in humans). Senescence represents a powerful defence against cancer and TBX2 may enhance the transforming effects of other oncogenes through bypass of the normal senescence default mechanisms (Serrano et al., 1997) . The cyclin-dependent kinase inhibitor p21 WAF1 is an important protein in cell senescence and TBX2 was shown to bind to and repress the p21 WAF1 promoter both in vitro and in vivo (Prince et al., 2004) and to have a role in maintaining proliferation and suppressing cell senescence in melanoma cells (Vance et al., 2005) . Recently, TBX2 has also been implicated in the promotion of anchorage-independent growth and in the bypass of apoptotic pathways in adrenocortical carcinomas (Ismail and Bateman, 2009) .
The early growth response (EGR) group of proteins are a family of zinc-finger transcription factors with multifunctional roles in proliferation, stress responses and apoptosis. The EGR family, of which EGR1 is the best characterized, function as a convergence point for many signalling cascades. EGR1 has both activation and repression domains. EGR1 is known to have important roles in growth control and has been shown to be a direct transcriptional regulator of many important tumour suppressor genes, including TP53, CDKN1A/p21
, TGF-b, and PTEN (de Belle et al., 1999) . Egr1-null mouse embryo fibroblasts bypass replicative senescence and show a loss of DNA damage response with an apparent immortal growth, suggesting loss of p53 functions (Krones-Herzig et al., 2003) . EGR1 is known to upregulate PTEN in response to ionizing radiation and to have a pivotal role in the regulation of PTEN through an Akt-ARF-EGR1-PTEN signalling axis (Virolle et al., 2001) . EGR1 has also been implicated in the upregulation of bax and the induction of apoptosis after ionizing radiation in prostate cancer cells (Zagurovskaya et al., 2009) .
In this study we show that TBX2 is a growthpromoting gene in breast cancer cells and is overexpressed in a number of breast cancer cell lines. We identified a number of novel transcriptional targets of TBX2 with reported roles in growth control, including the putative breast tumour suppressor NDRG1 (N-myc downregulated gene 1). Inhibition of TBX2 function by small interfering RNA (siRNA) knockdown or after expression of an inducible dominant-negative TBX2 results in a dramatic inhibition of cell growth accompanied by the onset of senescence and apoptosis. TBX2 represses NDRG1 not through direct promoter interaction but as a corepressor through recruitment of the transcription factor EGR1. This novel mechanism is highly significant because EGR1 directly regulates a number of key tumour breast suppressor genes (NDRG1, PTEN and p53). The importance of NDRG1 in growth control is showed by the fact that its reconstitution into TBX2-expressing breast cancer cell lines also results in growth inhibition. TBX2 repression of an EGR1-dependent transcriptional programme will therefore have profound implications for growth control and oncogenesis in breast tissue.
Results
Western blotting analysis showed that breast cancer cell lines with 17q23 amplification, such as MCF7 and MDA-MB-361, showed TBX2 protein expression ( Figure 1a ). This confirms earlier findings that 17q23 amplification correlated with TBX2 overexpression (Sinclair et al., 2002) . Southern blotting confirmed that both of these cell lines did indeed have an increased TBX2 copy number when compared with other breast cancer lines ( Figure 1b) . As expected, relative quantitative PCR analyses also showed that TBX2 protein expression correlated with cell lines with detectable mRNA expression (Figure 1c) . Previously, TBX2 has been shown to be required for the maintenance of proliferation and suppression of senescence in melanoma cells (Vance et al., 2005) . We performed TBX2 siRNA knockdown in three breast cancer cell lines and after confirming knockdown (Figure 1d) we assessed effects on cell growth using clonogenic assays. We observed dramatic growth inhibition in all three cell lines, even after only modest reduction in TBX2 mRNA levels, as for example, in BT474 cells (Figure 1e ), suggesting that TBX2 dosage may also be important. The efficacy of TBX2 knockdowns at the protein level is also shown (Figure 1f ). Several additional TBX2-specific siRNA oligonucleotides also showed TBX2 knockdown accompanied by inhibition of cell growth in MCF7 cells (data not shown). As a complementary approach to siRNA knockdown, we also generated an MCF7 cell line with tetracycline-inducible expression of a dominant-negative TBX2 containing an N-terminal Flag tag (DN-TBX2). After tetracycline-dependent expression of DN-TBX2 (Figure 1g) , we also observed an inhibition of clonogenic survival (Figure 1h ), confirming our observations with TBX2 siRNA that TBX2 is a growth-promoting/survival gene in these cells.
To identify novel TBX2 transcriptional targets we performed siRNA knockdown of TBX2 in MCF7 cells followed by microarray analysis. Knockdown of TBX2 was confirmed by western blotting analysis (Figure 2a) . We identified 488 genes that were upregulated and 160 that were downregulated at least twofold after TBX2 siRNA, consistent with its role as a transcriptional repressor. Interestingly, previously reported TBX2 target genes such as p14 ARF and Connexin43 did not seem to be TBX2 regulated in this study, whereas p21 WAF1/cip1 showed only a 1.5-fold upregulation and was not in our final data set. We selected a number of genes for validation as TBX2 targets from both the TBX2 siRNA upregulated and downregulated gene lists (Figures 2b and c, respectively ). We were particularly interested in targets from the upregulated gene list because these may contain genes that were more likely to be direct TBX2 targets. As Figure 2d shows, IGFBP3, NDRG1 and ERRF1 were also validated as TBX2 targets by northern blotting analysis. However, the most consistently TBX2-regulated gene was NDRG1, which showed consistent upregulation after TBX2 siRNA in several breast cancer cell lines (Figure 2e ). We also observed NDRG1 upregulation both at the mRNA and protein level after induction of DN-TBX2 in MCF7 cells (Figures 2f and g, respectively) . Together, these data show that TBX2 represses multiple target genes with NDRG1 consistently upregulated after TBX2 inhibition.
NDRG1 has been postulated to exert an effect as a tumour suppressor gene in breast tissue (Ronski et al., 2005; Lu et al., 2008) . We obtained two promoter luciferase constructs from Professor Max Costa (University of New York) containing the À257/ þ 4 and À80/ þ 4 proximal promoter regions of NDRG1. We cotransfected U2OS cells with constructs containing either an empty vector (pDEST) or FLAG-tagged TBX2 (TBX2) along with either the À80/ þ 4 or À257/ þ 4 promoter luciferase constructs. FLAG-TBX2 expression resulted in a significant reduction of NDRG1 protein expression (Figure 3a ) accompanied by significant decreases in luciferase activities of both À80/ þ 4 and À257/ þ 4 constructs (Figure 3b ), suggesting that the responsive element resided within the À80/ þ 4 region. The À80/ þ 4 sequence did not contain any putative TBX2 binding sites Prince et al., 2004) , but it did contain a fully conserved EGR1 consensus site (GCGGGGGCG). EGR1 has been previously shown to upregulate NDRG1 after hypoxia and iron chelation (Le and Richardson, 2004; Zhang et al., 2007) . Using the À80/ þ 4 construct we used sitedirected mutagenesis to generate an EGR1 point mutant (EGR1mut) and a deletion construct (À55/ þ 4) that completely removed the EGR1 site. Both constructs showed a significant reduction of basal NDRG1 promoter luciferase activity (Figure 3c ). Titration of TBX2 levels produced a dose-dependent repression of NDRG1 promoter luciferase activity in U2OS cells ( Figure 3d ). We postulated, therefore, that the EGR1 site is important for the basal and stress-induced regulation of NDRG1 and that TBX2 may target NDRG1 for repression through an EGR1-dependent mechanism. This is also indicated by the fact that EGR1 siRNA knockdown in U2OS cells results in reduced NDRG1 luciferase activity using the À80/ þ 4 construct (Figure 3e (i) ). The EGR family of transcription factors show overlapping specificities for DNA binding with EGR2 being the closest EGR1 functional homologue. To definitively show that EGR1 was the transcription factor specifically responsible for TBX2 repression, we performed EGR1-and EGR2-specific siRNA knockdown in MCF7 cells (Figure 3e (ii)). We observed NDRG1 upregulation only after EGR1 knockdown (Figure 3e (ii)). This was also confirmed at the protein level in which knockdown of EGR1 was accompanied by increased NDRG1 expression (Figure 3f ). Coimmunoprecipitation (Co-IP) experiments were then performed to test the theory that TBX2 interacts directly with EGR1. As Figure 3g shows, immunoprecipitation of EGR1 in MCF7 cells transfected with either an empty vector (EV) or FLAG-tagged TBX2 (FLAGTBX2) showed a specific association of EGR1 with FLAGTBX2 TBX2 represses NDRG1 to drive breast cancer proliferation KL Redmond et al after EGR1 pulldown (with mouse immunoglobulin G (IgG) pulldown as negative control). A reciprocal co-IP using a FLAG antibody was also able to show the EGR1-TBX2 interaction (Figure 3h ). Together, these data show that EGR1 is important for basal regulation of NDRG1 and the NDRG1 promoter is strongly repressed by TBX2. We also show for the first time that TBX2 and EGR1 physically interact. To show colocalization of endogenous TBX2 and EGR1 on the NDRG1 promoter we performed chromatin immunoprecipitation (ChIP) assay of the proximal NDRG1 promoter containing the EGR1 binding site. As Figure 4a shows, endogenous TBX2 and EGR1 could both be localized on the NDRG1 promoter. ChIP assay of an NDRG1 'upstream region' (at À1150/ À1000 bp relative to the NDRG1 transcriptional start) showed the specificity of this recruitment to the proximal promoter. To show the requirement for EGR1 for TBX2 recruitment to the NDRG1 promoter, we performed EGR1 siRNA knockdown in MCF7 cells ( Figure 4b ) followed by ChIP assay. As Figure 4c shows, knockdown of EGR1 resulted in a significant reduction of TBX2 recruitment, with the ChIP assay of the NDRG1 upstream region again serving as the corresponding negative control. We could also replicate these findings after TBX2 overexpression in U2OS cells (Figure 4d ). ChIP analysis again showed a significant reduction in recruitment of FLAG-TBX2 to the NDRG1 promoter in the absence of EGR1, with the accompanying NDRG1 upstream region. ChIP showing the specificity of the assay (Figure 4e ). Relative quantitative PCR quantification of these ChIP assays showed the efficacies of the EGR1 siRNA knockdowns as well as the reduction in TBX2 recruitment of TBX2 represses NDRG1 to drive breast cancer proliferation KL Redmond et al approximately four-and sixfold, respectively, for MCF7 and U2OS experiments (Figures 4f and g, respectively) . Together, these data show that EGR1 and TBX2 are both localized to the NDRG1 proximal promoter region and that TBX2 specifically requires EGR1 for recruitment. We wanted to assess the clinical implications of TBX2 expression as it is associated with poor prognosis in breast cancer and that NDRG1 has been shown to have important roles in differentiation, senescence and apoptosis (Stein et al., 2004; Zhang et al., 2008) . We induced a DN-TBX2 protein over 28 days and observed a dramatic induction of NDRG1 and a steady accumulation of proteins such as Dec1, p21 WAF1/cip1 and p53 (Figure 5a ). Dec1 is a basic helix-loop-helix transcription factor, a known p53-regulated gene implicated in p53-induced premature senescence (Qian et al., 2008) . In contrast, expression of the proliferation marker PCNA steadily decreased, indicating a slowdown of cell proliferation. The kinetics of upregulation of NDRG1 closely followed the expression of DN-TBX2 protein and indicated that it was more likely to be a direct transcriptional target when compared with markers such as Dec1, p53 and p21 WAF1/cip1 , which showed much slower upregulation, reflecting more indirect mechanisms. We also observed a cell death phenotype and could show clear evidence of PARP-1 (poly [ADP-ribose] polymerase 1) cleavage over a 6-day time course, suggesting apoptosis was also occurring (Figure 5b) . Apoptosis (possibly due to p53 activation) may contribute to the dramatic inhibition of proliferation observed in a 6-day growth curve (Figure 5c ) and FLAG-TBX2 in U2OS osteosarcoma cells transfected with FLAG-tagged TBX2 (FLAG-TBX2) and treated with EGR1 (EGR1si) or scrambled control (SCR) siRNA (GAPDH expression was used as loading control). (e) ChIP assay in U2OS cells showing localization of EGR1 (aEGR1) and exogenous TBX2 (aFLAG) on the NDRG1 promoter (NDRG1 PROM) after treatment with EGR1 (EGR1si) or scrambled control (SCR) siRNA. Inputs show equal DNA before immunoprecipitation. RNA pol II antibody used as a positive control; rabbit IgG and mouse IgG antibodies were used as negative controls. (f, g) RqPCR measurements of DNA samples from the ChIP assays described in (c) and (e), respectively. TBX2 represses NDRG1 to drive breast cancer proliferation KL Redmond et al whereas prolonged p53 activation may contribute to the gradual accumulation of senescence markers observed in Figure 5a . We also validated an EGR1-specific siRNA knockdown in MCF7 cells (Figure 5d ), which also resulted in a dramatic growth inhibition phenotype (Figure 5e ). In addition, EGR1 siRNA also produced changes in TBX2 target genes consistent with what we observed with TBX2 siRNA (Figure 5f ). Finally, using senescence-associated b-galactosidase staining we could also show that knockdown of either TBX2 or EGR1 by (Figure 5g ). Together, these data show that TBX2 and EGR1 expression is required to maintain cell proliferation and repress apoptosis or cellular senescence in TBX2-expressing breast cancer cells.
To show the role of NDRG1 as a potential cell growth regulator in breast cells we performed siRNA knockdown of NDRG1 followed by induction of DN-TBX2 (Figure 6a) . We observed in a growth curve over 6 days that we could restore cell proliferation by NDRG1 siRNA even in the presence of DN-TBX2 expression (Figure 6b) . We also performed transient transfection of NDRG1 into MCF7 cells that resulted in increased expression of Dec1, indicating that NDRG1 may contribute to the cell senescence observed after TBX2 inhibition (Figure 6c ). The strong and early induction of NDRG1 in MCF7 cells shown in Figure 5 after DN-TBX2 expression suggests that it may exert an effect as an important growth regulator. Indeed, we found a dramatic inhibition of cell proliferation after transient transfection of NDRG1 in MCF7 cells (Figure 6d ). These data highlight the importance of NDRG1 as a regulator of cell growth in breast tissue and show that the ability of TBX2 to target and repress NDRG1 will strongly promote oncogenesis.
Discussion
In this study we have shown that TBX2 drives cell proliferation and cell survival in breast cancer cell lines. We have described a novel mechanism of transcriptional repression by TBX2 through its interaction with the transcription factor EGR1. TBX2 exploits this interaction to target a number of important growth regulatory genes including NDRG1, a protein implicated in cell differentiation, apoptosis and senescence. We show by co-IP experiments that TBX2 and EGR1 physically interact. Moreover, by ChIP assay we show that TBX2 and EGR1 both localize to the NDRG1 proximal promoter and that TBX2 recruitment requires EGR1 expression. Abrogation of either TBX2 or EGR1 results in growth inhibition and the expression of cell senescence and apoptotic markers. Finally, we show the importance of NDRG1 as an effector of growth control downstream of TBX2-EGR1, as exogenous expression of NDRG1 can recapitulate growth inhibition and induce expression of a known cell senescence marker.
The canonical mechanism of TBX2 transcriptional repression is thought to be due to the ability of TBX2 to directly target promoters such as p21 WAF1/cip1 and p14 ARF through its T-box DNA binding domain (Vance et al., 2005) . TBX2 has been shown in embryonic tissues to cooperate with transcription factors, such as Msx1/ Msx2 or NKX2.5, with promoter binding sites adjacent to T-box sites to regulate genes such as Connexin43 and atrial natriuretic factor, respectively (Habets et al., 2002; Boogerd et al., 2008) . To the best of our knowledge, our study is the first to show that TBX2 is able to target genes independent of a T-box binding element through EGR1. This ability would greatly enhance the oncogenic potential of TBX2, given the importance of EGR1 as an upstream regulator of multiple important tumour suppressor genes. It is likely that TBX2 inhibits EGR1 function by altering chromatin modifications surrounding EGR1-regulated promoters. T-box proteins have been shown to control proliferation and differentiation through their ability to modulate histone methylation (Mikkelsen et al., 2007) . Indeed, expression of a DN-TBX2 induces senescence-associated foci expressing H3K9me3 and H3K27me3 co-incident with the inhibition of proliferation (Vance et al., 2005) . In addition, the TBX2 represses NDRG1 to drive breast cancer proliferation KL Redmond et al C-terminal region of TBX2 (amino acids 361-701) has been shown to co-immunoprecipitate with histone deacetylase 1 in mouse melanoma cells (Vance et al., 2005) . It would therefore be interesting to identify histone modifications on the NDRG1 promoter and other EGR1 targeted genes after TBX2 expression. It is noteworthy that other known TBX2 target genes (such as p21 WAF1/cip1 ) contain well-described EGR1 binding sites. The best-documented positive regulator of both p21 WAF1/cip1 and NDRG1 is p53, which in turn is also upregulated by EGR1, indicating the existence of multiple overlapping redundant pathways. For example, EGR1 has been shown to be a key regulator of p53 accumulation after insults such as ionizing radiation and hypoxia (Krones-Herzig et al., 2003; Yu et al., 2007) . In this study, induced expression of a DN-TBX2 over a 28-day period resulted in a gradual accumulation of p53 protein levels coincident with increased apoptosis and the expression of senescence markers such as Dec1. Exogenous expression of NDRG1 also resulted in an increase in the expression of Dec1, indicating that NDRG1 is an important regulator of cell senescence downstream of EGR1. Our observations may be due to the restoration of p53 function in MCF7 cells. However, we observed similar effects in p53-mutant breast cancer cell lines, indicating that p53 may only be one of the potential effector pathways.
The question remains of what is the significance of these findings in the context of normal breast biology and breast cancer? As TBX2 expression is primarily restricted to embryonic development, we propose that its re-expression after 17q23 amplification (or through other oncogenic events) would potentially allow escape from normal senescence/apoptotic default mechanisms. Other additional oncogenic events that would normally activate senescence checkpoints could occur unperturbed, as is the case for TBX3, which has been shown to collaborate with both c-myc and ras to enhance tumourigenesis (Carlson et al., 2002) . The TBX2-EGR1 interaction reported in this study would therefore simultaneously lead to the inhibition of multiple tumour suppressor pathways providing TBX2 with a mechanism to override normal growth control checkpoints. Abrogating this TBX2-EGR1 interaction or identifying pathways downstream amenable to therapeutic intervention may therefore present promising opportunities for the development of novel breast cancer treatments.
Materials and methods

Generation and maintenance of cell lines
The MCF-7, BT474, MDA-MB-157, MDA-MB-453, MDA-MB-231 and MDA-MB-468 breast cancer cell lines were maintained in Dulbecco's modied Eagle's medium; T47D, ZR75-1 breast cancer and U2OS osteosarcoma cell lines were maintained in RPMI. All were supplemented with 10% fetal calf serum, 1 mM sodium pyruvate, 50 mg/ml penicillinstreptomycin and 2 mM L-glutamine (Life Technologies, Inc., Paisley, UK). MCF7 dominant-negative TBX2 cells (MCF7-DN) were maintained in MCF7 media supplemented with G418, puromycin and tetracycline, at 1 mg/ml. To induce DN-TBX2, cells were cultured without addition of tetracycline. All were grown in 5% CO 2 in a humidified incubator.
RNA preparation and cDNA synthesis Total cellular RNA was extracted using the RNA STAT-60 reagent (Tel-Test, Inc., Friendswood, TX, USA) according to the manufacturer's instructions and complementary DNA (cDNA) was synthesized as previously described (Mullan et al., 2001) .
Real-time quantitative PCR
Relative quantitative PCR was performed on a 96-well plate (MJ Research, Waltham, MA, USA) on the Opticon DNA Engine Thermal Cycler (Bio-Rad, Hemel Hempstead, UK), and analysed using Opticon Monitor 2.02 software. Gene expression was determined relative to the expression of GAPDH (glyceraldehyde 3-phosphate dehydrogenase) and 18S. Primer sequences are shown in Supplementary Material.
Western blot analysis and antibodies
Protein lysates were extracted as described 
Short interfering RNA experiments
Cells were transfected on consecutive days with either a specific siRNA to the target gene or a scrambled control (SCR) using an oligofectamine-based protocol (Invitrogen, Paisley, UK). Cells were then harvested 72 h after the second transfection. TBX2, EGR1, EGR2, NDRG1 and scrambled control siRNA oligos were all purchased from Dharmacon DNA Technologies (Lafayette, CO, USA) (sequences in Supplementary Material).
Northern blotting RNA electrophoresis and northern blotting are as previously described (Mullan et al., 2001) . Probes were generated by restriction enzyme digest of IMAGE (Geneservice, Ltd, Cambridge, UK) cDNA clones (IGFBP3, ERRFI1), or from pcDNA3.1 cloned inserts (TBX2, NDRG1), or by PCR from MCF7 cDNA (GAPDH). Probes were labelled using the Megaprime DNA Labelling System (Amersham Biosciences, Buckinghamshire, UK) and 32P a-dCTP (Amersham) according to the manufacturer's instructions.
Southern blotting
Breast cancer cell lines were treated with lysis buffer (200 mg/ml Proteinase K, 1% SDS, 500 mM Tris, 20 mM EDTA, 10 mM sodium chloride (pH 9.0)). Genomic DNA was extracted with 1:1 phenol/chloroform, digested with 10 U/ml EcoRI/BglII (Invitrogen) to give average fragment size of 2 kb, and DNA electrophoresis was performed and transferred to Hybond-N membrane (Amersham Biosciences). Membranes were probed with an EcoRI/BglII-digested radiolabelled cDNA for human TBX2. A GAPDH probe was used to show equal loading of DNA.
Colony counts
Colony counts were performed as described (Buckley et al., 2007) .
Luciferase assays MCF7 and U2OS cells were seeded into six-well plates at a density of 300 000 cells/well, transfected with control (pGL3-basic empty vector) or containing the proximal promoter of NDRG1 cloned upstream of firefly luciferase and co-transfected with b-galactosidase expression constructs. The collection of samples and assay of luciferase activities are as previously described .
Site-directed mutagenesis Site-directed mutagenesis was carried out using Hot-Start KOD Polymerase (Novagen, Merck Chemicals Ltd., Nottingham, UK) according to the manufacturer's instructions. The putative EGR1 binding site in the NDRG1 promoter (forward primer, 5 0 -GGGGCGAGGCGCGTTTGCGGGGCCGC-3 0 underlined sequences showing the mutated bases) was mutated using the 80/ þ 4 NDRG1 luciferase promoter construct as template. The mutant construct sequenced to confirm base changes before being used in luciferase assays as described.
Co-immunoprecipitations MCF7 cells were transfected for 24 h with empty vector and FLAG-TBX2 pcDNA3.1. Whole cell lysates were prepared with ELB. For EGR1 IP, 50 ml sheep anti-rabbit IgG Dynabeads M-280 (Invitrogen) were conjugated with 3 mg of EGR1(44DS) rabbit monoclonal antibody (Cell Signalling) and 3 mg of negative control rabbit immunoglobulin fraction (Normal) (Dako, Glostrup, Denmark) for 2 h (4 1C). Beads were washed three times with ELB. Then, 1 mg of MCF7 lysate was precleared with sheep anti-rabbit IgG Dynabeads M-280 (Invitrogen) for 2 h, added to antibody-conjugated beads and rotated for 4 h (4 1C).
Beads were washed three times with ELB, resuspended in 20 ml of 10 Â protein sample buffer and boiled (95 1C for 10 min). Protein samples were then analysed by western blot analysis. For FLAG-TBX2 IP, 50 ml of sheep anti-mouse IgG Dynabeads (Invitrogen) were conjugated with 3 mg of FLAG (M2) mouse monoclonal antibody (Sigma) and 3 g of negative control mouse IgG1 (Dako), and washed and precleared with sheep anti-mouse IgG Dynabeads (Invitrogen) before adding to the antibody-conjugated beads (as for EGR1 IP).
Chromatin immunoprecipitations
This assay was carried out using the MCF7 and U2OS cell lines. This method has been described in detail elsewhere (Buckley et al., 2007) . Promoter primers were designed for (1) the NDRG1 proximal promoter region (encompassing EGR1 binding site) and (2) a region approximately 1000 bp upstream as a nonspecific ChIP assay control PCR (see Supplemental Material). Finally, PCR products were run on a 1.8% TBE agarose gel, and viewed (Syngene ChemiGenius, Cambridge, UK). The amount of NDRG1 promoter-specific product present in each ChIP was also quantitated using relative quantitative PCR.
Microarrays
Microarray analyses were performed as previously described (Kennedy et al., 2005) . Data were converted to expression measures using the MAS5.0 algorithm (GeneChip operating software version 1.1) and raw data were imported into the GeneSpring data analysis program version 6.1 (Silicon Genetics, Palo Alto, CA, USA). Parameters used for bioinformatic analysis are described in greater detail in Kennedy et al. (2005) .
Senescence staining
Senescence-associated b-galactosidase staining was carried out using the Senescence Detection Kit (Biovision, Mountain View, CA, USA, K320-250) according to the manufacturer's instructions.
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